INTRODUCTION
============

Ostrich (*Struthio camelus*) raising need experience and information from farmers and successful ostrich farming is largely dependent on the ability of farmers to rear sufficient numbers of viable and healthy chicks. However, high mortality of ostrich chicks particularly during the first months of life is a problem ([@b8]). Mortality can be reduced by correct housing, feeding and health management of chicks at hatch and during the brooding period, and some microorganisms were isolated and involved in ostrich chicks mortality ([@b19], [@b28]). Among microorganisms isolated from ostriches *E. coli* and staphylococci may colonize and eventually cause diseases in the host ([@b1], [@b17], [@b19]). *Staphylococcus aureus* can pose as an infectious agent due to virulence factors secreted by some clone and multidrug resistance is one of the main features ([@b20]). The bacteria can also secrete toxins with superantigenic properties ([@b10]), with enterotoxins secretion commanded by the *agr* loci after activation of RNA III Activating Protein -RAP ([@b7]). Anti-RAP antibodies inhibited in vivo infection caused by *S. aureus* in mouse ([@b6], [@b11]) and in vitro growth and secretion of enterotoxins by different strains of *S. aureus* were inhibited by specific antibodies developed against synthetic peptide RIP involved in *agr* activation ([@b27], [@b28]). *S. aureus* is also considered one of the main agents causing mastitis in cattle ([@b1], [@b29]). Diseases caused by *Escherichia coli* also pose as important losses for human and animals. Pathogenic strains enterotoxigenic *E*. *coli* (ETEC), enteropathogenic *E*. *coli* (EPEC), enteroinvasive *E. coli* (EIEC), enterohemorragic *E. coli* (EHEC), enteroagregative *E. coli* (EAEC) and extraintestinal patogenic *E. coli* (EXPEC) are among the causes of diarrhea in human and animal leading to economic loss for farmers, including birds and mammals ([@b18]). Antibodies developed against several microorganisms in chickens, also known as IgY, has been proved to be an alternative for immunological diagnostic tool, as well as suggested as immunotherapic purposes ([@b4], [@b12], [@b13], [@b15], [@b17], [@b21], [@b31]). The aim of this work was to demonstrate for the first time the inhibitory activity of polyclonal antibodies developed in ostriches against recombinant proteins recRAP and recSEC from *S. aureus* and recBFPA and recEspB from *E.coli*, towards clinical and standard strains of *S. aureus* and *E. coli* in vitro.

MATERIALS AND METHODS
=====================

Recombinant proteins/antigens
-----------------------------

Four ostriches in breeding season were immunized three times with recombinant proteins (200μg/animal) at intervals of 21 days in the brachial muscle of birds. The selected recombinant proteins were recSEC and recRAP derived from *S. aureus* and recEspB and recBFPA from *E. coli*, previously used by others ([@b2], [@b26]). From each female blood and non-fertilized eggs were collected before and after each immunization step, in order to obtain negative controls.

Immunization scheme
-------------------

Four ostriches were primed on day 0 by injecting 200μg of antigens previously incorporated in complete Freund\'s adjuvant into the wing muscle. The birds were subsequently injected two times with the antigens in physiological saline at 21 days intervals. Blood samples and eggs were collected immediately before and during the course of immunization. The blood was allowed to clot at room temperature and the centrifuged sera stored at -20° C. The collected eggs were stored at 4° C before being used to prepare IgY.

Purification of chicken IgY
---------------------------

The method used by others ([@b3], [@b27]) was carried out by diluting one part of egg yolk in nine equal volumes of distilled water, pH 5.0 to 6.0. The mixture was allowed to stand overnight at 4°C. Non-immunoglobulin proteins precipitated after centrifugation at 10,000 x*g* for 30 minutes at 4°C were discarded, and the supernatant was collected. Following the material rich in IgY antibodies was submitted to second precipitation step by two methodologies. After the mixtures were allowed to stand at room temperature, part was precipitated with 19% sodium sulphate solution (w/v) (Merck, Germany) and other part was precipitated with 20% ammonium sulphate solution (w/v) (Merck, Germany) and the precipitates containing IgY were dissolved in isotonic PBS, pH 7.5, and dialyzed at 4°C against the same buffer for three days. All samples were submitted to sterilization step by membrane filtration 0,22μm, and stocked at -20°C.

**Polyclonal antibodies titration:** All animals had the serum collected and tested for anti-recombinant proteins activities after a 10 days immunization period and their eggs.

**Immunochemical methods:** ELISA was performed as described ([@b3], [@b27]) using recombinant proteins, serum or yolk IgY antibodies obtained from the immunized ostriches, and goat anti-hen IgY (Sigma, USA) as reagents. Serum samples from previous non-immunized ostriches were used as negative controls.

Protein concentration assays
----------------------------

To determine protein concentration biscinchoninic acid assay (Sigma, USA) was performed according to instructions from mannufacturer. Detection of protein levels were read in a spectrophotometer at 570 nm (Dynatech MR 5000).

Bacterial inoculums
-------------------

Stocks of *S. aureus* from bacterial collection of Laboratory of Animal Health, FRI 361, a SEC producer strain, *S. aureus* LSA88 a bovine SEC/SED producer strain, *S. aureus* ATCC 25923, and two clinical *S. aureus* strains isolated from ostriches Saost1 e Saost2 were cultured in Brain Hearth Infusion broth (BHI, Acumedia, USA) overnight at 37°C. *E.coli* strains included EPEC (E2348/69), EAEC (O42), ETEC (H10407), EIEC (EDL1284), EHEC (EDL931), kindly furnished by Dra. Katia R.S. Aranda, from UNESP/Brazil) ([@b5]), cultured in BHI overnight at 37°C, were used in vitro on growth triplicate inhibition experiments.

IgY antibodies inhibitory activity
----------------------------------

From each stock of *S. aureus* and *E. coli* were prepared the inoculums in 0,85% saline solution, rendering approximately 1,5x10^8^ cells/mL, corresponding to photometric reading 0,5 McFarland concentration (DO~550nm~) (Densimat, Biomerieux, France) of each bacteria. Bacterial samples were cultured in BHI medium (Acumedia, USA) at 37°C, in a four hours incubation period in the presence of 50 μL of each IgY solution (5,0 mg/mL) under a constant shaking and growth followed by photometric reading (DO~550nm~). After reading, samples of treated cells were inoculated in PCA and McConkey agar medium, for *S. aureus* and *E. coli*, respectively, to evaluate cells viability. Statistical analyses used Tukey test (p\<0,05).

RESULTS AND DISCUSSION
======================

These results using bacteria strains from animal and human origin may represent an advance in the IgY techonology. Antibodies were developed in ostriches immunized with recombinant recSEC and recRAP proteins derived from *S. aureus*, and recBFPA and recEspB derived from *E. coli* and were purified from their egg yolk, aiming the development of alternative tools for diagnostic and treatment of infections caused by these pathogens. Results obtained by both sodium sulphate precipitation (SSP) and ammonium sulphate precipitation (ASP) methods, showed no significative differences by comparing the two preparations. Conversely, the results showed difference (p\<0,05) among specific IgY treated strains and non treated controls ([Figure 1](#fig1){ref-type="fig"} and [10](#fig6){ref-type="fig"}). IgY antibodies developed in chickens, using antigens from *S. aureus* were tested by several authors. Toxigenic *S. aureus* strains had their growth abrogated in vitro by native antigens of *S. aureus* ([@b9], [@b24], [@b32]). Others described antibodies from serum against native SEC ([@b23]) and recombinant SEC ([@b26]), but this is the first work to describe development of IgY in ostriches immunized with SEC recombinant protein, and tested against growth of *S. aureus* strains from different origin. Sugita-Konishi et al. ([@b24]) demonstrated the growth inhibition activity of IgY on SEA producer *S. aureus* strains. The study of Uhl et al. ([@b26]) showed that policlonal IgY from chicken not just recognized SEC-producer *S. aureus* strains, but also inhibited cell growth from different origins. Guimarães et al. ([@b9]) have suggested that IgY activity could be a result of interaction of antibodies with components present in bacterial surface, albeit the target molecule has not yet been defined. Sunwoo et al. ([@b25]) confirmed interference of growth, as result of interaction of IgY antibodies from hens and surface components of *E. coli* cells by electronic microscopy. [Figures 2](#fig2){ref-type="fig"} to [9](#fig5){ref-type="fig"} demonstrated the inhibition of cell growth of all staphylococcal cells used. The results of growth inhibition of *E. coli* from different sources were also observed by others by using IgY from chicken in vivo and in vitro assays ([@b4], [@b33]) and their therapeutic potential was suggested. Effects of IgY antibodies from chicken against *E.coli* strains conferring protection against gastrointestinal infections in different species as a food additive component ([@b14]), for treatment of diarrheic calves ([@b18]) and piglets ([@b16], [@b22]) were demonstrated. Our results showed in [figure 10](#fig6){ref-type="fig"} the inhibition (p\<0,05) of *E.coli* strains by comparing media of treatments with IgY before and IgY after treatment by S.A. and S.S. methods, respectively. The comparison between the two extraction methods there was no difference between the inhibition media. When the treated strains were compared among themselves it was observed that some strains presented higher difference between the inhibition media. [Figures 11](#fig7){ref-type="fig"} to [18](#fig10){ref-type="fig"} demonstrated the inhibition of cell growth of all *E. coli* cells used. Conversely, when difference between the media was compared using control and treated cells a significant difference was observed in all assays. Here the abrogation of cell growth by IgY antibodies from ostriches was demonstrated but further studies are needed to confirm the possible interaction with *S. aureus* and *E. coli* surface components. The actual literature of IgY technology lacks information of polyclonal IgY from ostriches that presents activity on growth inhibition of *S. aureus* and *E. coli*. The results presented clearly show an appropriate information and plausible application of IgY antibodies from ostriches as a tool for immunodiagnostic and therapy caused by these pathogenic agents.
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![Growth inhibition activity assays of anti SECrec IgY antibodies extracted from yolk of ostriches on *S. aureus* (Saost1) extracted by S.S. method from yolk of ostrich, pre and post treatment. On left (2 and 4) negative controls showing confluent growth of cells and on right (3 and 5) isolated colonies after treatments.](bjm-43-544-g003){#fig3}

![Showing growth inhibition activity assays of anti RAPrec antibodies extracted from yolk of ostriches on *S. aureus* (Saost2) extracted by A.S. method from yolk of ostrich, pre and e post treatment.](bjm-43-544-g004){#fig4}

![Growth inhibition activity assays of anti SECrec IgY antibodies extracted from yolk of ostriches on *S. aureus* (Saost1*)* extracted by A. S. method from yolk of ostrich, pre and post treatment. On left (6 and 8) negative controls showing confluent growth of cells and on right (7 and 9) isolated colonies after treatments.](bjm-43-544-g005){#fig5}

![Showing growth inhibition assay after 4 hours incubation with IgY antibodies anti EspBrec and BFPArec extracted from yolk of ostriches on E. *coli* strains extracted by A.S or S.S. methods. Media differences among DO~550nm~ pre and post treatment.](bjm-43-544-g006){#fig6}
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![Growth inhibition activity assays of anti EspBrec IgY antibodies extracted from yolk of ostriches on *E. coli* (EPEC) extracted by S.S. method from yolk of ostrich, pre and post treatment. On left (11 and 13) negative controls showing confluent growth of cells and on right (12 and 14) isolated colonies after treatments.](bjm-43-544-g008){#fig8}

![Showing growth inhibition activity assays of anti BFPArec IgY antibodies extracted from yolk of ostriches on *E. coli* (EPEC) extracted by A.S. method from yolk of ostrich, pre and e post treatment.](bjm-43-544-g009){#fig9}

![Growth inhibition activity assays of anti EspBrec IgY antibodies extracted from yolk of ostriches on *E. coli* (EPEC) extracted by A.S. method from yolk of ostrich, pre and post treatment. On left (15 and 17) negative controls showing confluent growth of cells and on right (16 and 18) isolated colonies after treatments.](bjm-43-544-g010){#fig10}

We thank to financial support to O.V.Motta by FAPERJ Editais Jovens Cientistas do Nosso Estado; Desenvolvimento Técnico Científico Regional; Grupos Emergentes and to the breeder Dr. Marconi Luna for animals and facilities availability to realize this work.
